Iodine-124

DRUG4 trials

Sponsors

Stanford University, Memorial Sloan Kettering Cancer Center, Thomas Hope

Conditions

Breast CancerBreast Cancer Early Stage Breast Cancer (Stage 1-3)Breast Cancer Metastatic Breast CancerMetastatic Thyroid CarcinomaThyroid CancerThyroid Carcinoma

Early Phase 1

Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT

TerminatedNCT00725946

Stanford UniversityBreast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic Breast Cancer

Start: 2008-02-29End: 2012-12-31Updated: 2017-10-11

Phase 1

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

RecruitingNCT03647358

Memorial Sloan Kettering Cancer CenterMetastatic Thyroid Carcinoma, Thyroid Carcinoma

Start: 2018-08-21End: 2027-08-01Target: 60Updated: 2026-03-20

Phase 2

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

RecruitingNCT06961084

Thomas HopeThyroid Cancer

Start: 2025-07-14End: 2026-03-31Target: 62Updated: 2026-01-07

Unknown Phase

Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA

WithdrawnNCT00373711

Stanford UniversityThyroid Cancer

Start: 2007-05-31Updated: 2022-06-21

Related Papers

[<sup>18</sup>F]TFB PET/CT misses intense [<sup>124</sup>I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer.

2024-10-08

The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients.

2023-05-126 citations